Scopus BioPharma

Executive Summary

Scopus BioPharma is a private, clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York. The company specializes in developing transformative RNA and gene therapy-based treatments for serious diseases with high unmet medical need, with its lead program focused on targeted immuno-oncology gene therapy for multiple cancers. Although specific pipeline details and clinical trial phases are not publicly disclosed, Scopus BioPharma's strategic focus on combination gene and immunotherapy positions it within a rapidly evolving oncology landscape. As a privately held entity, the company relies on private funding and partnerships to advance its candidates. The absence of publicly available financial data or traded securities limits visibility, but the company's alignment with cutting-edge modalities suggests potential if clinical proof-of-concept is achieved. Given the early stage and competitive gene therapy field, the outlook remains speculative, with success hinging on forthcoming clinical data and capital access.

Upcoming Catalysts (preview)

• Q2 2026Lead Program Phase 1 Data Readout30% success
• Q3 2026Series A/B Financing Announcement50% success
• H2 2026Strategic Partnership or Licensing Deal25% success